G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 478.2 INR 0.69% Market Closed
Market Cap: 417.1B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note

Relative Value

The Relative Value of one GLENMARK stock under the Base Case scenario is 1 170.3 INR. Compared to the current market price of 1 478.2 INR, Glenmark Pharmaceuticals Ltd is Overvalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLENMARK Relative Value
Base Case
1 170.3 INR
Overvaluation 21%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
4
vs Industry
35
Median 3Y
1.1
Median 5Y
1.2
Industry
2.5
Forward
2.9
vs History
vs Industry
0
Median 3Y
13.6
Median 5Y
13.7
Industry
21.9
Forward
29
vs History
vs Industry
7
Median 3Y
11.5
Median 5Y
11.1
Industry
16.5
vs History
vs Industry
35
Median 3Y
-11
Median 5Y
-11
Industry
23.6
vs History
4
vs Industry
14
Median 3Y
1.7
Median 5Y
2
Industry
2.1
vs History
4
vs Industry
35
Median 3Y
1.3
Median 5Y
1.3
Industry
2.6
Forward
2.8
vs History
4
vs Industry
40
Median 3Y
2
Median 5Y
2
Industry
5.2
vs History
4
vs Industry
11
Median 3Y
8.3
Median 5Y
8.3
Industry
13.3
Forward
15.8
vs History
4
vs Industry
6
Median 3Y
10.6
Median 5Y
10.2
Industry
16.6
Forward
19.4
vs History
vs Industry
7
Median 3Y
12.6
Median 5Y
12.4
Industry
15.6
vs History
vs Industry
0
Median 3Y
28.7
Median 5Y
34.2
Industry
19.1
vs History
4
vs Industry
21
Median 3Y
1.2
Median 5Y
1.3
Industry
1.9

Multiples Across Competitors

GLENMARK Competitors Multiples
Glenmark Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
417.1B INR 3.5 -31.8 28.2 50.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
IN
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Average P/E: 32.4
Negative Multiple: -31.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top